Levodopa gains psychostimulant-like properties after nigral dopaminergic loss

Annals of Neurology

Volumn 74, Issue 1, 2013, Pages 140-144

  Engeln, Michel ^a,b,d   Fasano, Stefania ^c   Ahmed, Serge H ^a,b,d   Cador, Martine ^b,d   Baekelandt, Veerle ^e   Bezard, Erwan ^a,b,d,f   Fernagut, Pierre Olivier ^a,b,d  

^a INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^b CNRS   (France)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; GENE OVEREXPRESSION; MALE; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; REWARD; SUBSTANTIA NIGRA PARS COMPACTA; SWEETNESS; TASTE PREFERENCE;

ADENOVIRIDAE; ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FOOD PREFERENCES; HUMANS; LEVODOPA; MALE; MUTATION; PARKINSON DISEASE; RATS; RATS, WISTAR; REWARD; SACCHARIN; SUBSTANTIA NIGRA; SWEETENING AGENTS; TASTE; TRANSDUCTION, GENETIC; TYROSINE 3-MONOOXYGENASE; UBIQUITIN;

EID: 84883285757     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23881     Document Type: Article

References (20)

1. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinsons disease: reward systems gone awry? Lancet Neurol 2003;2:595-604.
2. OSullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157-170.
3. Giovannoni G, OSullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinsons disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.
4. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinsons disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009;8:1140-1149.
5. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995;15(5 pt 2):3863-3875.
6. Engeln M, Ahmed SH, Vouillac C, et al. Reinforcing properties of pramipexole in normal and parkinsonian rats. Neurobiol Dis 2012;49C:79-86.
7. Fasano S, DAntoni A, Orban PC, et al. Ras-guanine nucleotidereleasing factor 1 (Ras-GRF1) controls activation of extracellular signal-regulated kinase (ERK) signaling in the striatum and longterm behavioral responses to cocaine. Biol Psychiatry 2009;66:758-768.
8. Vendruscolo LF, Gueye AB, Darnaudery M, et al. Sugar overconsumption during adolescence selectively alters motivation and reward function in adult rats. PLoS One 2010;5:e9296.
9. Evans AH, Lawrence AD, Cresswell SA, et al. Compulsive use of dopaminergic drug therapy in Parkinsons disease: reward and anti-reward. Mov Disord 2010;25:867-876.
10. Liggins J, Pihl RO, Benkelfat C, Leyton M. The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers. PLoS One 2012;7:e28370.
11. Iversen SD, Creese I. Behavioral correlates of dopaminergic supersensitivity. Adv Neurol 1975;9:81-92.
12. Costall B, Naylor RJ. Actions of dopaminergic agonists on motor function. Adv Neurol 1975;9:285-297.
13. Roberts DC, Koob GF, Klonoff P, Fibiger HC. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol Biochem Behav 1980;12:781-787.
14. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-858.
15. Heffner TG, Zigmond MJ, Stricker EM. Effects of dopaminergic agonists and antagonists of feeding in intact and 6-hydroxydopamine- treated rats. J Pharmacol Exp Ther 1977;201:386-399.
16. Wise RA. Dual roles of dopamine in food and drug seeking: the drive-reward paradox. Biol Psychiatry 2012 Oct 5. doi: 10.1016/ j.biopsych.2012.09.001. [Epub ahead of print]
17. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004;9:557-569.
18. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed: Waltham, MA: Academic Press, 2009.
19. Lundblad M, Decressac M, Mattsson B, Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 2012;109:3213-3219.
20. Decressac M, Mattsson B, Bjorklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alphasynuclein rat models of Parkinsons disease. Exp Neurol 2012;235:306-315.